Novo Nordisk buys drug factory in North Carolina for assistance in manufacturing, packaging new diabetes drug

The tablet version of Novo Nordisk diabetes drug, known as semaglutide, is an important growth prospect for the Danish drugmaker, which faces pressure on prices from competitors and U.S. lawmakers, who have been critical of rising drug costs.

COPENHAGEN: Novo Nordisk said on Tuesday that it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

The tablet version of its diabetes drug, known as semaglutide, is an important growth prospect for the Danish drugmaker, which faces pressure on prices from competitors and U.S. lawmakers, who have been critical of rising drug costs.

Novo, the world's biggest producer of diabetes drugs, said the new plant near Durham would receive shipments of the active pharmaceutical ingredient needed to produce the pill from another factory under construction in North Carolina.

"We want to build manufacturing capacity in the United States so that we can establish a local U.S. supply chain for oral semaglutide and other future oral products," Novo Nordisk vice president Henrik Steen Jensen told Reuters.

Novo submitted its oral semaglutide drug for approval in the United States in March and hopes to begin local production in 2021, Jensen said.

Read Also: Novo Nordisk Q1 profit tops forecast as new diabetes drug Ozempic shines

The tablet, which Novo currently produces only in Denmark, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production.

So far, all have been via injection and a pill would make it quicker and easier for diabetics to take their medication.

Novo said it bought the plant in Durham from Purdue Pharma but did not disclose the price or capacity.

Read Also: Novo Nordisk gets USFDA for use of Victoza to treat type 2 diabetes in pediatric patients